期刊文献+

siRNA沉默ENAH基因对肝癌细胞生长的抑制作用

Inhibition of ENAH gene silenced by siRNA on growth of liver cancer cell
原文传递
导出
摘要 目的探讨siRNA沉默ENAH基因对肝癌细胞生长的抑制作用。方法采用脂质体Lipofectamine 2000将ENAH-siRNA及control-siRNA转染至人肝癌细胞HCCLM3,分别设为ENAHsiRNA组和control-siRNA组。采用Western blot检测ENAH蛋白表达,采用裸鼠成瘤实验观察肝癌细胞致瘤能力。记录肿瘤体积,绘制生长曲线,进行生存分析。两组实验数据比较采用t检验,生存分析采用Kaplan-Meier法和Log-rank检验。结果 ENAH-siRNA组细胞ENAH蛋白表达明显弱于controlsiRNA组。ENAH-siRNA组裸鼠接种后实体肿瘤形成时间为(24±3)d,明显长于control-siRNA组的(8±2)d(t=12.55,P〈0.05)。ENAH-siRNA组裸鼠中位生存时间为64(48~81)d,control-siRNA组为34(21~48)d,两组总体生存率比较差异有统计学意义(χ2=14.33,P〈0.05)。结论 siRNA沉默ENAH基因可明显减弱肝癌细胞的致瘤能力,抑制肿瘤生长。 Objective To investigate the inhibition of ENAH gene silenced by siRNA on the growth of liver cancer cell. Methods ENAH-siRNA and control-siRNA were transfected to human liver cancer cell HCCLM3 using liposome Lipofectamine 2000 and ENAH-siRNA group and control-siRNA group were established. The expression of ENAH protein was detected by Western blot. Tumorigenic ability of the liver cancer cell was observed through nude mice tumorigenicity assay. Tumor volume was recorded, growth curve was drawn and survival analysis was conducted. The experimental data of two groups were compared using t test, and the survival analysis was conducted using Kaplan-Meier method and Log-rank test. Results The expression of ENAH protein in ENAH- siRNA group was significantly less than that in control-siRNA group. The formation time of solid tumor after inoculation in nude mice in ENAH-siRNA group was (24±3) d, which was significantly longer than (8±2) d in control-siRNA group (t=12.55, P〈0.05). The median survival time of the nude mice was 64 (48 ± 81) d in ENAH-siRNA group and was 34 (21 ± 48) d in control-siRNA group. There was significant difference in the overall survival rate between two groups (x^2=14.33, P〈0.05). Conclusion ENAH gene silenced by siRNA may obviously weaken the tumorigenic ability of liver cancer cell and inhibit the growth of tumor.
出处 《中华肝脏外科手术学电子杂志》 CAS 2015年第4期246-249,共4页 Chinese Journal of Hepatic Surgery(Electronic Edition)
基金 教育部博士点基金新教师类(20110171120089)
关键词 肝肿瘤 致癌性试验 生长曲线表 裸鼠 Liver neoplasms Carcinogenicity tests Growth charts Nude mouse
  • 相关文献

参考文献4

二级参考文献53

  • 1郑克立,王长希,陈立中,唐孝达,范昱,闵志廉,齐隽,黎磊石,刘志红,季曙明.雷帕霉素联合环孢素和皮质类固醇预防肾移植急性排斥反应的临床研究[J].中华器官移植杂志,2004,25(4):240-242. 被引量:10
  • 2Jian Zhou Jia Fan Zheng Wang Zhi-Quan Wu Shuang-Jian Qiu Xiao-Wu Huang Yao Yu Jian Sun Yong-Sheng Xiao Yi-Feng He Yu-Qi Wang Zhao-You Tang.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma:Report of an initial experience[J].World Journal of Gastroenterology,2006,12(19):3114-3118. 被引量:20
  • 3汤钊猷.开展肝癌转移复发研究的意义与途径[J].中华普通外科杂志,2006,21(11):761-761. 被引量:34
  • 4Faivre S,Rarmond E,Boucher E,et al.Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma:an open-label,muhiceatre,phase Ⅱ study.Lancet Oncol,2009,10(8):794-800.
  • 5Uematsu S,Higashi T,Nouso K,et al.Altered expression of vascular endothelial growth factor,fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.J Gastroenterol Hepato1,2005,20(4):583-588.
  • 6Park JW,Finn RS,Kim JS,et al.Phase Ⅱ,open-label study of brivanib as first-line therapy in patients with advanced hepatocellulas carcinoma.Clin Cancer Res,2011,17(7):1973-1983.
  • 7Toh H,CP,Carr BI,Knox JJ,et al.A phase Ⅱ study of ABT869 in advanced hepatocellular carcinoma(HCC):Interim analysis.ASCO 2009,May 29 to June 2,2009,Orlando[C].Chicago:ASCO,2009.
  • 8Abou-Alfa GK,Johnson P,Knox JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial.JAMA,2010,304(19):2154-2160.
  • 9Yau T,CP,Cheung FY,Lee AS,et al.Phase Ⅱ trial of sorafenib with capecitabine and oxaliplatin(SECOX)in patients with locally advanced or metastatic hepatocellular carcinoma.Joint ECCO 15-34th ESMO Multidisciplinary Congress,Septmber 19-23,2009[C].Berlin:European Journal of Cancer Supplements,2009.
  • 10Thomas MB,Morris JS,Chadha R,et al.Phase Ⅱ trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.J Clin Oncol,2009,27(6):843-850.

共引文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部